Risk network approaches to locating undiagnosed HIV cases in Odessa, Ukraine

Pavlo Smyrnov, Leslie D Williams, Ania Korobchuk, Yana Sazonova, Georgios K Nikolopoulos, Britt Skaathun, Ethan Morgan, John Schneider, Tetyana I Vasylyeva, Samuel R Friedman, Pavlo Smyrnov, Leslie D Williams, Ania Korobchuk, Yana Sazonova, Georgios K Nikolopoulos, Britt Skaathun, Ethan Morgan, John Schneider, Tetyana I Vasylyeva, Samuel R Friedman

Abstract

Introduction: Providing HIV healthcare and Treatment as Prevention both depend on diagnosing HIV cases, preferably soon after initial infection. We hypothesized that tracing risk networks recruits higher proportions of undiagnosed positives than outreach-based testing or respondent-driven sampling (RDS) in Odessa, Ukraine.

Methods: The Transmission Reduction Intervention Project (TRIP) used risk network tracing to recruit sexual and injection networks of recently-infected and longer-term infected (LTs) seeds (2013 to 2016). Integrated Biobehavioural Surveillance (IBBS) (2013) used RDS to recruit people who inject drugs (PWID). Outreach Testing tested PWID for HIV at community outreach sites (2013 to 2016). Proportions of undiagnosed positives among those tested were compared TRIP versus IBBS; TRIP versus Outreach Testing and between TRIP arms. Costs were compared across the projects.

Results: TRIP tested 1252 people (21% women) in seeds' risk networks; IBBS tested 400 (18% women); Outreach Testing 13,936 (31% women). TRIP networks included a higher proportion of undiagnosed positives (14.6%) than IBBS (5.0%) or Outreach Testing (2.4%); odds ratio (OR) 3.25 (95% CI 2.07, 5.12) versus IBBS and 7.03 (CI 5.95, 8.31) versus Outreach Testing respectively. Findings remained significant in analyses stratified by sex and when PWID in TRIP networks were compared with Outreach Testing and IBBS. Within TRIP, recently-infected participants' networks contained higher proportions of undiagnosed positives (16.3%) than LTs' networks (12.2%); OR 1.41 (CI 1.01, 1.95). TRIP located undiagnosed positives less expensively than did RDS or Outreach Testing.

Conclusions: TRIP's recruiting techniques, including prioritizing networks of the recently infected, find undiagnosed HIV-positive people efficiently. They should be integrated with standard practice to improve case-finding. Research should test these techniques in other socio-epidemiologic contexts.

Clinical trial registry: Registered ClinicalTrials.gov: NCT01827228.

Keywords: HIV diagnosis; HIV prevention; early infection; risk networks; social network; treatment as prevention.

© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

References

    1. UNAIDS . Fast‐Track: ending the AIDS epidemic by 2030. [cited 2016 Dec 30/]. Available from:
    1. Nikolopoulos GN, Pavlitina E, Muth SQ, Schneider J, Psichogiou M, Williams LD, et al. A network intervention that locates and intervenes with recently HIV‐infected persons: the Transmission Reduction Intervention Project (TRIP). Sci Rep. 2016;6:38100.
    1. Green N, Hoenigl M, Chaillon A, Anderson CM, Kosakovsky Pond SL, Smith DM, et al. Partner services in adults with acute and early HIV infection. AIDS. 2017;31(2):287–93.
    1. Friedman SR, Downing MJ Jr, Smyrnov P, Nikolopoulos G, Schneider JA, Livak B, et al. Socially‐integrated transdisciplinary HIV prevention. AIDS Behav. 2014;18:1821–34.
    1. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta‐analysis of high‐risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446–53.
    1. Ghosh D, Krishnan A, Gibson B, Brown SE, Latkin CA, Altice FL. Social network strategies to address HIV prevention and treatment continuum of care among at‐risk and HIV‐infected substance users: a systematic scoping review. AIDS Behav. 21(4):1183–207.
    1. Latkin CA, Forman V, Knowlton A, Sherman S. Norms, social networks, and HIV‐related risk behaviors among urban disadvantaged drug users. Soc Sci Med. 2003;56(3):465–76.
    1. Latkin CA, Knowlton AR. Micro‐social structural approaches to HIV prevention: a social ecological perspective. AIDS Care. 2005;17(sup1):102–13.
    1. Neaigus A, Friedman SR, Curtis R, Des Jarlais DC, Furst RT, Jose B, et al. The relevance of drug injectors’ social and risk networks for understanding and preventing HIV infection. Soc Sci Med. 1994;38(1):67–78.
    1. Schneider J, Cornwell B, Jonas A, Lancki N, Behler R, Skaathun B, et al. Network dynamics of HIV risk and prevention in a population‐based cohort of young Black men who have sex with men. Netw Sci. 2017;5:1–29.
    1. Williams LD. Understanding the relationships among HIV/AIDS‐related stigma, health service utilization, and HIV prevalence and incidence in Sub‐Saharan Africa: a multi‐level theoretical perspective. Am J Community Psychol. 2014;53(1–2):146–58.
    1. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. High rates of forward transmission events after acute/early HIV‐1 infection. J Infect Dis. 2007;195:951–9.
    1. Hollingsworth TD, Anderson RM, Fraser C. HIV‐1 transmission, by stage of infection. J Infect Dis. 2008;198:687–93.
    1. Marzel A, Shilaih M, Yang WL, Böni J, Yerly S, Klimkait T, et al. HIV‐1 transmission during recent infection and during treatment interruptions as major drivers of new infections in the Swiss HIV Cohort Study. Clin Infect Dis. 2016;62:115–22.
    1. Vasylyeva TI, Friedman SR, Lourenco J, Gupta S, Hatzakis A, Pybus OG, et al. Reducing HIV infection in people who inject drugs is impossible without targeting recently‐infected subjects. AIDS. 2016;30(18):2885–90.
    1. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV‐1 transmission per coital act, by stage of HIV‐1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9):1403–9.
    1. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis. 2010;202 Suppl 2:S270–7.
    1. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire‐Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921–9.
    1. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, et al. Determinants of per‐coital‐act HIV‐1 infectivity among African HIV‐1‐serodiscordant couples. J Infect Dis. 2012;205:358–65.
    1. Koopman JS, Jacquez JA, Welch GW, Simon CP, Foxman B, Pollock SM, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:249–58.
    1. Shelley LI. Organized crime and corruption in Ukraine: impediments to the development of a free market economy. Demokratizatsiya 1998;6(4):648–63.
    1. ECDC (2016) HIV/AIDS surveillance in Europe 2015. (European Centre for Disease Prevention and Control/WHO Regional Office for Europe, Stockholm: ).
    1. Barnett T, Whiteside A, Khodakevich L, Kruglov Y, Steshenko V. The HIV/AIDS epidemic in Ukraine: its potential social and economic impact. Soc Sci Med. 2000;51(9):1387–403.
    1. Booth RE, Kwiatkowski CF, Mikulich‐Gilbertson SK, Brewster JT, Salomonsen‐Sautel S, Corsi KF, et al. Predictors of risky needle use following interventions with injection drug users in Ukraine. Drug Alcohol Depend. 2006;82:S49–55.
    1. Dehne KL, Grund JPC, Khodakevich L, Kobyshcha Y. The HIV/AIDS epidemic among drug injectors in Eastern Europe: patterns, trends and determinants. J Drug Issues. 1999;29(4):729–76.
    1. Nikolopoulos GK, Kostaki EG, Paraskevis D. Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia. Infect Genet Evol. 2016;46:256–68.
    1. Vitek CR, Jurja‐Ivana Čakalo J‐I, Dumchev KV, Salyuk TO, Božičević I, Baughman AL, et al. Slowing of the HIV epidemic in Ukraine: evidence from case reporting and key population surveys, 2005‐2012. PLoS One. 2014;9(9):e103657.
    1. Duong YT, Kassanjee R, Welte A, Morgan M, De A, Dobbs T, et al. Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV‐1 subtypes. PLoS One. 2015;10:e0114947.
    1. Gile K, Johnston LG, Salganik MJ. Diagnostics for respondent‐driven sampling. J R Stat Soc Ser A Stat Soc [Internet]. 2015; 178(1):241–69. Available from:
    1. Tabana H, Nkonki L, Hongoro C, Doherty T, Ekström AM, Naik R, et al. A cost‐effectiveness analysis of a home‐based HIV counselling and testing intervention versus the standard (facility based) HIV testing strategy in rural South Africa. PLoS One. 2015;10(8):e0135048.
    1. Daniel WW. Biostatistics: a foundation for analysis in the health sciences, 8th edn Hoboken, NJ: John Wiley & Sons; 2005. 638–41 pp.
    1. Frieden TR, Das‐Douglas M, Kellerman SE, Henning KJ. Applying public health principles to the HIV epidemic. N Engl J Med. 2005;353(22):2397–402.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV‐1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
    1. INSIGHT START Study Group , Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
    1. TEMPRANO ANRS 12136 Study Group , Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–22.
    1. Centers for Disease Control . Recommendations for partner services programs for HIV infection, syphilis, gonorrhea, and chlamydial infection. MMWR Recomm Rep. 2008; 57:1–83; quiz CE1–4.
    1. Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev. 2013;10:CD002843.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel